The pro-inflammatory cytokine, tumor necrosis factor-*α* (TNF*α*), was first characterized by its cytotoxic ability to induce cancer cell apoptosis.^[@bib1]^ TNF*α* is known to have a role in the maintenance of tissue homeostasis. Dysregulation of TNF*α* contributes to the pathogenesis of several diseases, such as cancer, cardiovascular, neurological and metabolic disorders.^[@bib2],\ [@bib3]^ TNF*α* is primarily produced by activated macrophages in response to microbial infection and inflammation. TNF*α* signaling is critical for repair of injured lesions. However, sustained TNF*α* stimulation may also lead to endothelial cell (EC) dysfunction and the inhibition of angiogenesis.^[@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ Moreover, long-term TNF*α* treatment in breast cancer cells inhibits global protein synthesis and selectively activates apoptotic signals to promote cell death.^[@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13]^ However, a detailed mechanism that links TNF*α*-regulated protein synthesis and apoptosis is still elusive.

The conjugation of TNF*α* to its cognate receptors, TNFR1/TNFR2, activates TNFR downstream signaling cascades that include activating NF-*κ*B, caspases, c-Jun N-terminal kinase (JNK), p38 MAPK and extracellular signal-regulated kinase (ERK), depending on cell type-specific responses.^[@bib3]^ Generally, caspases, JNK and p38 are apoptotic mediators involved in cytokine and stress-mediated apoptosis, whereas ERK kinase and NF-*κ*B are mainly responsible for cell survival in response to mitogenic stimuli.^[@bib14],\ [@bib15],\ [@bib16]^ The mechanisms by which p38 promotes apoptosis are complex and involve its ability to regulate transcription, protein synthesis and turnover through its downstream kinases.^[@bib17]^

The promyelocytic leukemia (PML) protein is a tumor suppressor that functions as a transcription regulator in response to environmental stimuli.^[@bib18]^ A significant fraction of PML is enriched in subnuclear structures known as the PML nuclear bodies (PML NBs). These are nuclear depots for a variety of proteins that move in and out in response to stimuli.^[@bib19]^ PML NBs control the storage of nuclear proteins that await recruitment in response to a wide variety of cellular signalings and can serve as sites for post-translational modification of proteins including acetylation and sumoylation.^[@bib20],\ [@bib21],\ [@bib22]^ Thus, PML and PML NBs regulate fundamental cellular processes such as transcription, DNA replication and cell cycle progression.^[@bib18]^ Disruption of PML NBs has serious consequences that ultimately alter cell fate.^[@bib11]^ In contrast, overexpression of PML results in cell growth arrest, senescence and apoptosis.^[@bib8],\ [@bib22],\ [@bib23]^ Histochemical studies indicated that PML is maintained at low levels in most examined tissues and cancer cells, but is expressed at a higher level in inflammation-associated tissues including macrophages and vascular endothelium, suggesting an important role for PML in tumorigenesis, inflammatory responses and endothelial function.^[@bib4],\ [@bib24],\ [@bib25]^ We and others have shown that PML protein is subjected to extensive stability regulation.^[@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ It was previously reported that TNF*α* induced PML protein accumulation and PML NB formation in human umbilical endothelial cells (HUVECs).^[@bib4]^ Our previous report demonstrated the TNF*α* induced PML protein accumulation partly through transcriptional control,^[@bib4]^ suggesting that post-transcriptional regulation also plays a role in this process.

Internal ribosome entry site (IRES)-mediated translation via mRNA 5′-UTRs is a mechanism to selectively increase expression of apoptosis-associated proteins when cells are under stresses such as oxidative stress and genotoxic stress,^[@bib30],\ [@bib31]^ conditions known to downregulate global translation. For example, *c-myc*, *DAP5*, *APAF-1*, *XIAP* and *p53* have been reported to switch from cap-dependent translation to IRES-mediated translation in response to apoptotic stimulation.^[@bib31],\ [@bib32],\ [@bib33],\ [@bib34],\ [@bib35]^ TNF*α* downstream MAPK kinases such as p38, ERK and MAP kinase-activated protein kinase 1 (MNK1) selectively increase IRES-mediated translation of a subset of mRNAs.^[@bib36],\ [@bib37]^ As PML is known to promote cell death in response to apoptotic stimulation, it is likely that TNF*α* induces PML protein accumulation through a translation-dependent mechanism.

In this study, we dissect the mechanisms underlying transcription-independent regulation of PML in response to TNF*α* stimulation. We demonstrate that MNK1, a p38 downstream kinase, plays a pivotal role in TNF*α*-mediated accumulation of PML by activating an IRES in the 5′-UTR of *PML* mRNA to increase PML protein accumulation. Through this mechanism, the TNF*α*--MNK1--PML axis regulates the expression of histone deacetylase 7 (HDAC7) target genes including *MCP-1* and *MMP10* and controls migration and capillary tube formation in ECs. Furthermore, activation of the PML IRES by MNK1 promotes TNF*α*-induced cell death and contributes to MCF7 apoptosis.

Results
=======

TNF*α* enhances PML protein accumulation via both transcription-dependent and -independent mechanisms
-----------------------------------------------------------------------------------------------------

We have previously shown that TNF*α* induced a twofold increase in *PML* mRNA, whereas PML protein expression is elevated to an even greater extent. Indeed, in HUVECs, PML protein continued to accumulate throughout the time course of exposure ([Figure 1a](#fig1){ref-type="fig"}), but the *PML* mRNA levels plateaued at 4 h of TNF*α* treatment ([Figure 1b](#fig1){ref-type="fig"}). Similar observations were noted in HeLa cells ([Figures 1c and d](#fig1){ref-type="fig"}). These data suggest that TNF*α* induces PML protein accumulation in both transcription-dependent and -independent manners. To test whether protein stability control is involved in TNF*α*-mediated PML protein accumulation, we examined the PML protein half-life with or without TNF*α* stimulation. Using cychloheximide treatment, which blocks translation, we observed little difference in the PML protein half-life with or without TNF*α* treatment in HeLa cells and HUVECs ([Figures 1e and f](#fig1){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Taken together, these data suggested that TNF*α*-induced PML protein accumulation is at least partially due to translational control.

TNF*α*-induced PML accumulation is p38 kinase dependent
-------------------------------------------------------

Several TNF*α* downstream MAPK kinases, including JNK, ERK and p38, have been reported to mediate protein or mRNA regulation in mammalian cells.^[@bib38],\ [@bib39]^ To determine which kinase is involved in TNF*α*-mediated induction of PML protein, we first carried out kinase inhibitor screenings with or without TNF*α* treatment. We found that the blockade of p38 (SB202190) and ERK2 (U0126) kinases in HUVECs effectively reduced TNF*α*-induced PML accumulation 7- and 2.3-fold, respectively ([Figure 2a](#fig2){ref-type="fig"}). We focused on p38 kinase in the following studies. The efficacy of the kinase inhibitors was confirmed by the disappearance of kinase activation markers in western blots ([Figure 2b](#fig2){ref-type="fig"} and [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Using an siRNA approach, we further validated that the induction of PML by TNF*α* is p38 dependent ([Figure 2c](#fig2){ref-type="fig"}). Immunofluorescence microscopy studies also demonstrated that the PML NB formation tightly correlates with the abundance of PML in response to TNF*α* treatment and *p38* knockdown ([Supplementary Figure 4a](#sup1){ref-type="supplementary-material"}). A previous report indicated that a fraction of PML was found in the endoplasmic reticulum (ER) of mouse embryonic fibroblasts (MEFs).^[@bib40]^ Using confocal microscopy and subcellular fractionation experiments, we observed that endogenous PML predominantly localizes in the nucleus with or without TNF*α* treatment. We did not observe PML in the cytoplasm or ER in HUVECs or MCF7 cells, although we cannot exclude the possibility that a residual fraction of PML is present in the ER ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Based on these data, we conclude that p38 is indispensable for TNF*α*-mediated induction of nuclear PML protein accumulation.

MNK1 is a p38 downstream kinase responsible for TNF*α*-mediated PML upregulation
--------------------------------------------------------------------------------

In [Figure 2c](#fig2){ref-type="fig"} and [Supplementary Figure 4a](#sup1){ref-type="supplementary-material"}, we observed that PML protein in HUVECs accumulated in PML NBs and decreased in *p38* knockdown cells. Furthermore, subcellular fractionation also indicated that most PML protein was detected in the nuclear fraction and was upregulated by TNF*α* and inhibition of p38 compromised TNF*α*-mediated accumulation of PML protein ([Figure 3a](#fig3){ref-type="fig"}). Four kinases, including casein kinase 2 (CK2), MNK1, mitogen and stress-activated protein kinase (MSK1) and MAPKAP kinase 2 (MK2), are p38 downstream kinases that mediate various aspects of p38 activity.^[@bib15],\ [@bib41]^ To further determine which kinase plays a key role in TNF*α* regulation of PML, we blocked the p38 downstream kinase activity individually, either by kinase inhibitors or siRNAs. From these inhibition assays, we concluded that inhibition of CK2, MSK1 and MK2 had little or no effect on TNF*α*-mediated PML protein accumulation ([Figures 3b--d](#fig3){ref-type="fig"}). In contrast, inhibition of MNK1 kinase (MNKi) activity by CGP57380 ([Supplementary Figure 3c](#sup1){ref-type="supplementary-material"}) attenuated TNF*α* effects on the accumulation of nuclear PML protein ([Figure 3e](#fig3){ref-type="fig"}). This is similar to the effect of the p38 inhibitor, SB202190 ([Figures 3a and e](#fig3){ref-type="fig"}). To further confirm a role of MNK1 kinase in TNF*α*-mediated regulation of PML, we carried out knockdown studies and found that the depletion of *MNK1* reduced TNF*α* effects on PML protein accumulation but not on its mRNA abundance ([Figure 3f](#fig3){ref-type="fig"}). The TNF*α*-induced and MNK1-dependent PML protein accumulation is not due to an increase in PML protein stability because knockdown of *MNK1* had little or no effect on PML protein half-life after TNF*α* stimulation ([Figure 3g](#fig3){ref-type="fig"}). In addition to MNK1, we also found that knockdown of the *MNK1* paralog, *MNK2*, in HUVECs reduced TNF*α*-induced PML protein accumulation without affecting its mRNA levels ([Figures 3h--j](#fig3){ref-type="fig"}). Furthermore, polysome analyses demonstrated that TNF*α* stimulation increased the presence of *PML* mRNA in heavy polysome but this increase is abolished by MNK1 inhibitor CGP57380 ([Figure 3k](#fig3){ref-type="fig"}).

MNK1 kinase regulates the TNF*α*-induced activity of an IRES located within the PML 5′-UTR
------------------------------------------------------------------------------------------

MNK1 kinase has been reported to promote protein synthesis through the activation of a subset of IRESs, although the detailed mechanism remains unknown.^[@bib36],\ [@bib42]^ We first explored whether human *PML* 5′-UTR has an IRES using a bicistronic luciferase reporter system ([Figure 4a](#fig4){ref-type="fig"}). This reporter contains an upstream *Renilla* luciferase (*RLuc*) gene, which is translated in a cap-dependent manner, fused with the Firefly luciferase (*FLuc*) gene, which can only be translated when the intra-cistronic sequence contains a functional IRES. One needs to be cautious as the putative intra-cistronic IRES may harbor a putative cryptic promoter.^[@bib43]^ To test this possibility, we generated expression constructs in which several truncated human *PML* 5′-UTR fragments were inserted immediately upstream of the FLuc gene in a pGL3-basic reporter plasmid that does not contain any promoter sequence. We were able to determine that the -100-\>-1 region of the *PML* 5′-UTR (140 nucleotides) contains no detectable promoter activity when compared with an empty vector in HeLa cells ([Supplementary Figure 5a](#sup1){ref-type="supplementary-material"}) and HUVECs ([Supplementary Figure 5b](#sup1){ref-type="supplementary-material"}). In contrast, -140-\>-1 of *PML* 5′-UTR construct expresses significant reporter activity. Together, these data suggest that -140-\>-100 of *PML* 5′-UTR contains a cryptic promoter. When introducing pRF bicistronic reporter into the *RLuc* knockdown HeLa cells, we observed that the *FLuc* activity driven by *PML* 5′-UTR (-100-\>-1) and *EMCV* IRES are largely decreased in parallel to *Renilla* luciferase reduction. This result suggests that neither *PML* 5′-UTR (-100-\>-1) nor *EMCV* IRES contains a cryptic promoter ([Figure 4d](#fig4){ref-type="fig"}).^[@bib44]^ Importantly, the *PML* 5′-UTR (-100-\>-1)-pRF exhibited substantially higher levels of IRES activity than both positive controls, *EMCV* IRES or the *p53* IRES in HeLa cells ([Supplementary Figure 5c](#sup1){ref-type="supplementary-material"}) and HUVECs ([Figure 4b](#fig4){ref-type="fig"}). Furthermore, we demonstrated that the detected FLuc reporter activity in our bicistronic system is not derived from spurious splicing or a leaky ribosomal read-through ([Figures 4c and e](#fig4){ref-type="fig"} and [Supplementary Figure 6](#sup1){ref-type="supplementary-material"}).^[@bib45]^ To further strengthen our conclusion, we transfected *in vitro* transcribed bicistronic mRNAs into HeLa cells and demonstrated that the Firefly luciferase activity driven by *EMCV* IRES and *PML* 5′-UTR (-100-\>-1) were substantially higher than pRF, regardless of whether the mRNA was capped ([Figure 4f](#fig4){ref-type="fig"}). In summary, we conclude that the *PML* 5′-UTR (-100-\>-1) contains an IRES.

To determine whether the *PML* IRES responds to TNF*α*, the *PML* 5′-UTR (-100-\>-1)-pRF reporter construct was transfected into HeLa cells with or without TNF*α* treatment. Upon TNF*α* stimulation, *PML* 5′-UTR (-100-\>-1)-pRF showed 1.8- and 2.3-fold increases in reporter activity at 24 and 48 h of TNF*α* treatment, respectively, but the increase in FLuc/RLuc by TNF*α* was attenuated when *MNK1* was knocked down. This result indicated that the *PML* 5′-UTR (-100-\>-1) is activated through a MNK-dependent mechanism in response to TNF*α* treatment ([Figure 4g](#fig4){ref-type="fig"}). The translation initiation factor eIF4E is a major substrate of MNK1. However, it is unclear whether eIF4E is involved in this process. To examine this possibility, we co-transfected *PML* 5′-UTR (-100-\>-1)-pRF with the eIF4E inhibitor, 4E-BP, and a mutant defective in mTORC1 phosphorylation, 4E-BP(5A). This 4E-BP mutant sequesters and reduces eIF4E-mediated cap-dependent mRNA translation.^[@bib46],\ [@bib47]^ As shown in [Figure 4h](#fig4){ref-type="fig"}, 4E-BP or 4E-BP (5A) had little or no effect on TNF*α*-mediated induction of endogenous PML protein accumulation ([Figure 4h](#fig4){ref-type="fig"}). Reporter assays further suggested that TNF*α*-mediated PML IRES activation is eIF4E independent ([Figure 4i](#fig4){ref-type="fig"}). These data suggest that eIF4E has a minimal role in TNF*α*-induced, IRES-mediated *PML* mRNA translation.

MNK1 kinase contributes to TNF*α*-induced PML accumulation for its function in the inhibition of HUVEC migration and *in vitro* network formation
-------------------------------------------------------------------------------------------------------------------------------------------------

We have previously shown that PML is essential for TNF*α*-mediated inhibition of EC migration and capillary network formation,^[@bib4],\ [@bib25]^ both of which are key processes in angiogenesis. In parallel with the ability of TNF*α* to induce PML protein accumulation ([Figure 1a](#fig1){ref-type="fig"}), TNF*α* inhibits EC migration and capillary tube formation in a time-dependent manner ([Figures 5a--c](#fig5){ref-type="fig"}). To dissect whether MNK1 plays a role in these two EC activities, we knocked down *MNK1* and *PML* in HUVECs and compared their effects on TNF*α*-mediated inhibition of angiogenesis. As expected, knockdown of *PML* in HUVECs largely attenuated TNF*α*-mediated inhibition of HUVEC migration and *in vitro* capillary network formation ([Figures 5d--f](#fig5){ref-type="fig"}). Consistently, knockdown of *MNK1* in HUVECs also compromised TNF*α* inhibitory effects on cell migration and capillary network formation ([Figures 5e and f](#fig5){ref-type="fig"}). Similar to previous reports, TNF*α* treatment in our assays did not induce HUVEC apoptosis or senescence ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}).^[@bib7],\ [@bib48]^ Taken together, these data suggested that the MNK1--PML axis contributes to the TNF*α*-mediated inhibition of angiogenesis.

MMP10 and MCP-1 are TNF*α*-induced genes targeted by p38--MNK1--PML axis
------------------------------------------------------------------------

Our finding that MNK1 potentiates TNF*α*-mediated induction of PML protein accumulation raised the possibility that MNK1 plays a role in TNF*α--*PML axis to regulate expression of PML-associated genes, thus contributing to TNF*α*-mediated regulation of EC biology. To test this, we first analyzed the gene expression profiles in HUVECs and identified a list of chemokine and angiostatic genes that are positively regulated by both TNF*α* and PML.^[@bib25]^ In addition to *MMP10*, expression of *PDGFB*, *CXCL11*, *CXCLR4* and *MCP-1* was downregulated in *PML* knockdown HUVECs ([Supplementary Figure 9a](#sup1){ref-type="supplementary-material"}). We focused on two genes, *MMP10* and *MCP-1*, for further analyses because the functions of these two genes in ECs are well characterized.^[@bib49],\ [@bib50],\ [@bib51]^ Using two independent *PML* shRNAs, we further confirmed that *MMP10* and *MCP-1* were PML downstream target genes ([Figure 6a](#fig6){ref-type="fig"}). Moreover, TNF*α*-mediated upregulation of *MMP10* and *MCP-1* mRNAs was significantly reduced in cells pretreated with inhibitors of p38 or MNK1 ([Figure 6b](#fig6){ref-type="fig"}) and cells in which *MNK1* was knocked down ([Figure 6c](#fig6){ref-type="fig"}). Based on these data, we conclude that *MMP10* and *MCP-1* mRNAs are induced by TNF*α* in a p38-, MNK1- and PML-dependent manner.

The expression of MMP10 and MCP1 is controlled by TNF*α*-MNK1-PML axis via HDAC7
--------------------------------------------------------------------------------

The induction of PML and PML NBs by stress stimuli can increase the sequestration of several PML-associated transcription regulators, preventing access to chromatin and thus contributing to the alterations in the expression of a subset of PML-responsive genes.^[@bib18]^ Our previous studies suggested that HDAC7 is a PML-associated protein and that upregulation of PML causes the derepression of HDAC7 target genes ([Supplementary Figure 9b](#sup1){ref-type="supplementary-material"}).^[@bib5],\ [@bib26]^ We therefore investigated whether HDAC7 participates in TNF*α*- and PML-mediated induction of *MMP10* and *MCP-1* mRNA expression. By analyzing the promoters of *MCP-1* from human, mouse and chimpanzee, we identified putative binding sites for transcription factors MEF-2, GATAs and BCL6 that have been shown to bind class II HDACs ([Figure 7a](#fig7){ref-type="fig"}).^[@bib52]^ Using chromatin immunoprecipitation (ChIP) assays, we observed HDAC7 binding to the *MCP-1* promoter at two regions, approximately −1.2 and −1.6 kb upstream of *MCP-1* transcription start site. However, these associations were disrupted by TNF*α* treatment ([Figure 7a](#fig7){ref-type="fig"}). Furthermore, knockdown of *PML* increased HDAC7 occupancy on both *MMP10* and *MCP-1* promoters and neutralized TNF*α* effects on the recruitment of HDAC7 to the *MCP-1* and *MMP10* promoters. This indicates that PML negatively regulates the recruitment of HDAC7 to the *MMP10* and *MCP-1* promoters ([Figures 7b and c](#fig7){ref-type="fig"}). Finally, we carried out double knockdown experiments followed by TNF*α* treatment and found that further knockdown of *HDAC7* under a *PML* or *MNK1* knockdown background rescued *MCP-1* and *MMP10* expression in HUVECs ([Figure 7d](#fig7){ref-type="fig"}). In summary, our data demonstrated that TNF*α*-induced *MCP-1* and *MMP10* expression is regulated by the MNK1--PML--HDAC7 regulatory network.

MNK1 contributes to TNF*α*-induced PML protein accumulation and inhibition in MCF7 breast cancer
------------------------------------------------------------------------------------------------

Because PML is a well-known tumor suppressor, we next examined whether this TNF*α*-mediated regulation of PML also occurs in cancer cells. We first examined the TNF*α*-induced PML accumulation in MCF7 breast cancer cells because of the ability of this cancer cell line to respond to TNF*α* treatment.^[@bib9],\ [@bib53]^ Similar to what we observed in HUVECs, the PML protein level was significantly upregulated in TNF*α*-treated MCF7 cells, and was attenuated by inhibitors of p38 and MNK1 ([Figure 8a](#fig8){ref-type="fig"} and [Supplementary Figure 11](#sup1){ref-type="supplementary-material"}). In addition, knockdown of MNK1 by sh*MNK1* blocked TNF*α*-mediated induction of PML, without decreasing *PML* mRNA ([Figure 8b](#fig8){ref-type="fig"}). Consistently, *PML* 5′-UTR (-100-\>-1)-pRF showed a 1.8-fold increase in relative reporter activity after 24 h of TNF*α* treatment in MCF7 cells. However, the increase in FLuc/RLuc by TNF*α* was attenuated when *MNK1* was inactivated. This result indicates that the *PML* 5′-UTR (-100-\>-1) IRES activity is induced through a MNK1-dependent mechanism in response to TNF*α* treatment ([Figure 8c](#fig8){ref-type="fig"}). To determine biological significance of TNF*α*--MNK1--PML axis in MCF7 cells, we performed viability assays by Trypan blue exclusion. We found that TNF*α* treatment of MCF7 cells results in 50% of the cells undergoing cell death, and knockdown of *MNK1* or *PML* partially alleviated this effect ([Figure 8d](#fig8){ref-type="fig"}). Furthermore, knockdown by sh*MNK1* or sh*PML* mitigated TNF*α*-induced cleavage of PARP1, a PML-associated apoptotic effector ([Figure 8e](#fig8){ref-type="fig"}).^[@bib20]^ In addition, inhibition of MNK1 activity by CGP57380 also attenuated TNF*α* cytotoxicity on MCF7 cells ([Figure 8f](#fig8){ref-type="fig"}).

The effect of TNF*α* and MNK1 inhibitor on proliferation of HL60 and NB4 cells
------------------------------------------------------------------------------

To extend our findings, we determined the effect of TNF*α*, CGP57380 or both on the survival of hematopoietic cancer cells, HL60 and NB4 cells. HL60 cells expressing wild-type PML were sensitive to TNF*α* treatment as previously reported and CGP57380 attenuated TNF*α* effects on the inhibition of HL60 cell proliferation ([Figure 8g](#fig8){ref-type="fig"}).^[@bib54]^ In contrast, NB4 cells, which express a PML--RAR*α* fusion, demonstrated resistance to TNF*α* and CGP57380 treatment. Interestingly, cotreatment of both reagents led to a significant inhibition of cell growth in NB4 cells, suggesting that the TNF*α*--MNK1--PML axis regulates proliferation of these cells ([Figure 8h](#fig8){ref-type="fig"}). In summary, these data support a model in which the p38--MNK1--PML axis mediates TNF*α*-induced MCF7 cell death in good correlation with regulation of the activity of an IRES that was described for the first time in this report to be present within 100 nucleotides upstream of the PML translational initiation codon.

Discussion
==========

In the present study, we have identified an IRES in human *PML* 5′-UTR spanning -100-\>-1 nucleotides upstream of the translational initiation codon. Notably, this IRES is activated by the TNF*α*--p38--MNK1 axis, in agreement with induced translation of the *PML* mRNA and PML protein, thus contributing to TNF*α*-regulated cancer cell apoptosis and inhibition of EC migration and capillary tube formation ([Figure 8i](#fig8){ref-type="fig"}).

Several reports have suggested that MNK1-mediated phosphorylation of eIF4E contributes to protein synthesis and cell growth.^[@bib55],\ [@bib56]^ Interestingly, *Mnk1*^*−/−*^ *Mnk2*^*−/−*^ mice are viable, fertile and developmentally normal despite the absence of phosphorylated eIF4E, and neither *de novo* protein synthesis nor cap-dependent translation was affected in *Mnk1*^*−/−*^ *Mnk2*^*−/−*^ MEFs.^[@bib56]^ These results suggest that MNK1 may not directly participate in cap-dependent translation. In contrast, several lines of evidence have demonstrated that MNK1 may have a role in cap-independent translational control.^[@bib36],\ [@bib57]^ It has been shown that overexpression of MNK1 increased cap-independent translation compared with cap-dependent translation.^[@bib58]^ In this study, we propose that MNK1 is a critical effector that potentiates TNF*α*-mediated *PML* mRNA translation through the *PML* IRES ([Figures 4](#fig4){ref-type="fig"} and [8](#fig8){ref-type="fig"} and [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). It has been previously shown that PML has the ability to sequester eIF4E to PML NBs, thereby blocking eIF4E-mediated nuclear export of a subset of mRNAs.^[@bib59],\ [@bib60]^ We speculate that MNK1 promotes IRES-dependent *PML* mRNA translation and PML-mediated eIF4E nuclear retention contributes to the MNK1-mediated inhibition of a subset of mRNA translation.

It has been shown that TNF*α* stimulation in T cells forms a positive feed-forward loop that activates *TNFα* mRNA translation via MNK1 and its 3′-UTR.^[@bib61]^ This finding raises the possibility that IRES translation is part of a positive feed-forward loop that contributes to TNF*α*-mediated PML protein accumulation in HUVECs. Unlike T cells, our data suggested that TNF*α*-mediated PML protein accumulation is eIF4E independent. First, TNF*α* induces PML protein accumulation in a time-dependent manner that continues beyond 4 h of TNF*α* treatment, when the active form of eIF4E (p-eIF4E) is significantly decreased ([Figures 1b and d](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"} and [Supplementary Figure 7c](#sup1){ref-type="supplementary-material"}). Second, a previous report has shown that TNF*α* stimulation in MCF7 cells results in a decrease in 4E-BP phosphorylation that promotes the ability of 4E-BP to sequester and suppress eIF4E.^[@bib9],\ [@bib62]^ However, we demonstrated that with an ectopically expressed 4E-BP mutant, 4E-BP (5A) that is devoid of phosphorylation by mTORC1, TNF*α*-mediated PML protein accumulation and *PML* IRES activation behaves similarly to the 4E-BP-transfected cells ([Figures 4h--i](#fig4){ref-type="fig"}).

Mouse PML has been found localized in the ER of MEFs and contributes to cell apoptosis.^[@bib40]^ In our study, we were unable to detect endogenous PML in the ER of HUVECs or MCF7 cells ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). This observation suggests that the ability of PML-mediated TNF*α* cytotoxic activity in MCF7 cells does not involve the previously described cytoplasmic PML. The mouse *Pml* 5′-UTR has been shown to mediate oncogenic RAS-induced *PML* mRNA translation through an mTOR kinase cascade,^[@bib63]^ but the detailed mechanism is not clear. The human *PML* 5′-UTR is 140 nucleotides long, 40 nucleotides longer than the mouse *Pml*. Using bicistronic reporter assays, we have mapped a *bona fide* IRES to human *PML* 5′-UTR (-100-\>-1) region. We used stringent criteria to determine the human functional *PML IRES*. First, we excluded the possibility that human *PML* 5′-UTR (-100-\>-1) region contains any cryptic promoter activity by employing a promoterless reporter assay ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Furthermore, direct transfection of *in vitro* synthesized bicistronic mRNAs demonstrated that *PML* 5′-UTR (-100-\>-1) harbors an IRES ([Figure 4f](#fig4){ref-type="fig"}). Sequence alignment of *PML* 5′-UTR from several mammals revealed that the *PML* 5′-UTR (-100-\>-1) region is highly conserved, with the exception of the mouse *PML* 5′-UTR that is loosely conserved ([Supplementary Figure 10a](#sup1){ref-type="supplementary-material"}). A free energy and secondary structure prediction revealed that the *PML* 5′-UTR (-100-\>-1) region contains two structural elements, namely two stem loops connected by an open loop, that may be the possible structural requirement for ribosome entry ([Supplementary Figure 10b](#sup1){ref-type="supplementary-material"}).^[@bib64],\ [@bib65]^ All known *PML* isoforms are the products of alternative splicing of C-terminal exons from a primary *PML* transcript and there have been no reports of *PML* isoforms with a different 5′-UTR.^[@bib66]^ Thus, it is likely that IRES-mediated translational regulation applies to all isoforms. The IRES-mediated mRNA translation mainly occurs when cells confront different stresses, such as hypoxia and a cytotoxic reagent treatment.^[@bib67]^ The IRES-mediated *PML* mRNA translation observed here is proposed to have a dominant role in PML protein production for cell growth control under these conditions. In summary, we conclude that the *PML* 5′UTR (-100-\>-1) region contains a functional IRES and is likely part of the underlying mechanism that controls the accumulation of PML protein.

Several studies suggested that targeting *MNK1* represents a novel strategy to inhibit tumor growth.^[@bib68],\ [@bib69],\ [@bib70]^ Breast cancer cell lines such as SKBr3 or BT474 showed sensitivity to MNK1 inhibitor CGP57380-mediated anti-proliferation.^[@bib68]^ However, MCF7 cells are resistant to CGP57380 treatment. In our study, CGP57380 treatment in MCF7 cells attenuated TNF*α*-induced cell death and PML accumulation and caused a decrease in the *PML* IRES response to TNF*α* ([Figures 4](#fig4){ref-type="fig"} and [8](#fig8){ref-type="fig"} and [Supplementary Figure 11](#sup1){ref-type="supplementary-material"}). In addition, knockdown of *MNK1* by shRNAs reduced TNF*α*-mediated PARP1 activation and subsequently protected MCF7 cells from TNF*α*-induced cell death ([Figures 8d--f](#fig8){ref-type="fig"}). Taken together, these results suggested that the antibreast cancer activity by MNK1 inhibitors is cell subtype dependent. This precaution is also likely to be true when treating leukemia patients with IFN*α* or IFN*γ* because inhibition of MNK1 activity also compromised IFN-mediated suppression of leukemic progenitor cells.^[@bib71]^ Consistent with a previous report, we demonstrate that TNF*α* significantly inhibits HL60 cell growth, whereas it has little or no effect on NB4 cells that express PML--RAR*α* fusion protein.^[@bib72]^ Interestingly, TNF*α* and CGP57380 synergistically inhibit NB4 cell proliferation. We suspect that the CGP57380-mediated increase in cytotoxicity to TNF*α* is, in part, due to the inhibition of *PML--RARα* mRNA translation through the 5′-UTR IRES ([Figure 8h](#fig8){ref-type="fig"}).^[@bib73]^ Accordingly, inhibitors of MNK1 could be a promising adjuvant agent against some subtypes of leukemia or cancers in which the *PML* gene harbors dominant-negative, gain-of-function mutations.

Our data also indicate that MNK1 plays a key role in TNF*α*-mediated suppression of angiogenesis and EC migration ([Figure 5](#fig5){ref-type="fig"}). However, unlike its cytotoxic effects on cancer cells, TNF*α* does not induce apoptosis or senescence in primary cells, including endothelial cells under our assay conditions ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}).^[@bib7],\ [@bib9],\ [@bib54],\ [@bib74]^ We propose that a potential mechanism to regulate angiogenesis by TNF*α* is through the regulation of angiogenesis-associated gene expression.^[@bib4],\ [@bib25]^ Indeed, using ChIP assays and qRT-PCR, we demonstrated that *MMP10* and *MCP-1* are TNF*α*-inducible genes that are regulated by the MNK1--PML--HDAC7 axis in HUVECs ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} and [Supplementary Figure 9](#sup1){ref-type="supplementary-material"}). Notably, MCP-1 and MMP10 are multifunctional effectors involved in various physiological and pathological processes, including sustained EC activation, endothelium dysfunction and vascular permeability.^[@bib49]--[@bib51],\ [@bib75],\ [@bib76]^ Our study reveal a novel mechanism by which the MNK1--PML--HDAC7 cascade mediates TNF*α*-induced gene expression and provides several possible routes targeting *MCP-1* to attenuate the vascular complications in different inflammation-associated diseases.

Materials and Methods
=====================

Plasmids and DNA constructs
---------------------------

The expression plasmids are listed in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. The PCR fragments of *PML* 5′-UTR were amplified using HEK293T genomic DNA as a template. For bicistronic plasmids, PCR products were digested by restriction enzymes, *Eco*RI and *Nco*I, and subcloned into the pRF plasmid to replace the EMCV IRES, a gift from Dr. Mazumder (Cleveland, OH, USA). The *p53* IRES and hairpin were generated as previously reported and subcloned into the pRF plasmid.^[@bib77],\ [@bib78]^ The shRNA plasmids were purchased from Sigma (St. Louis, MO, USA) and their related information is listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. All clones were sequenced to confirm their identity.

Cell lines, reagents and antibodies
-----------------------------------

HEK293T, MCF7 and HeLa cells were purchased from ATCC (Manassas, VA, USA) and cultured in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum (FBS), 50 U of penicillin G/ml and 50 *μ*g of streptomycin sulfate at 37 °C in 5% CO~2~. HUVECs were purchased from Lonza and cultured in endothelial cell basal medium (EBM-2; Lonza, Boston, MA, USA) with EGM-2 SingleQuot growth supplements (Lonza, Madison, WI, USA). Cells that were \<6 passages were used in this study. TNF*α* was purchased from Promega (G5421, Madison, WI, USA). The kinase inhibitors used in this study are: p38 kinase (SB202190; Sigma), CKII (TBCA; Calbiochem, San Diego, CA, USA), MSK (SB747651; Tocris Bioscience, Bristol, UK), JNKs (SP600125; Sigma); ERKs (U0126; Sigma) and MNK (CGP57380; Cayman Chemical, Ann Arbor, MI, USA; or cercosporamide; Tocris Bioscience). The siRNAs were purchased from Thermo Scientific (Waltham, MA, USA) and the siRNA target sequences are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Antibodies used in this study are listed in the [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. The transfection reagents DharmaFECT1 (T-2001) and Lipofectamine 2000 (LF2000) were purchased from Thermo Scientific and Invitrogen (Grand Island, NY, USA), respectively.

Cycloheximide treatment
-----------------------

Cells were treated with or without TNF*α* followed by 40 *μ*M cycloheximide (Sigma) treatment for the indicated times and harvested 16 h after TNF*α* treatment. Whole-cell lysates were subjected to western blotting with anti-PML and anti-*β*-actin antibodies. The intensity was quantified by ImageJ (National Institute of Health, Bethesda, MD, USA).

Kinase inhibition and TNF*α* treatment
--------------------------------------

Cells were transiently transfected with kinase-specific siRNAs for 48 h or pretreated with kinase inhibitors for 1 h before TNF*α* treatment. The kinase inhibitor concentration used in this study is 10 *μ*M unless specifically noted. For HUVECs, the cells were treated with TNF*α* (20 ng/ml) for 16 h. MCF7 and HeLa cells were treated with TNF*α* 60 ng/ml for 48 h or an indicated time.

siRNA knockdown and cellular protein extraction
-----------------------------------------------

For siRNA knockdown, a nontargeting siRNA or two independent siRNAs against target genes (Thermo Scientific) were transfected into HUVECs using DF1 transfection reagent (Thermo Scientific) according to the manufacture\'s protocol. Cells were treated with TNF*α* for 16 h and harvested 72 h after siRNA transfection before preparation of total RNA or whole-cell extracts. *Renilla* luciferase knockdown by pBS/U6-RLi was performed as previously reported.^[@bib44]^ For whole-cell extracts, cells were resuspended in RIPA buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) plus protease inhibitors (Roche, Nutley, NJ, USA) on ice for 35 min and vortexed every 5 min until completely homogenized. The cell lysates were mixed with an equal volume of 2 × SDS buffer (100 mM Tris-Cl, pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol and 2% *β*-mercaptoethanol) and boiled in a hot pot for 10 min. For western blots, *β*-actin or *α*-tubulin were included as internal loading controls.

Lentivirus preparation for shRNA knockdown
------------------------------------------

The shRNAs expressing plasmids were purchased from Sigma and the targeted sequences are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. To generate infectious viral particles expressing shRNAs, we individually cotransfected the shRNA plasmid into HEK293T cells with packaging vectors pMD2G and ps-PAX-2 by Lipofectamine 2000 according to the manufacture\'s protocol (Invitrogen). The conditioned medium containing the lentivirus was collected 40 h after transfection. After removing cell debris by passage through a 0.45 *μ*m filter, the medium was diluted with culture medium in a 1 : 4 ratio for viral infection. At 6 h after viral infection, the medium was replaced with fresh medium and cells were allowed to recover overnight followed by puromycin selection for an additional 48 h. After puromycin selection, the medium was removed and replaced with fresh medium. Cells were cultured overnight in regular medium before further experiments.

Total RNA extraction, RT-PCR and quantitative real-time PCR (qRT-PCR)
---------------------------------------------------------------------

At 72 h after transient transfection or infection with siRNAs or shRNAs respectively, HUVECs, HeLa and MCF7 cells were harvested, total RNA prepared using PrepEase RNA Spin kits (USB/Affymetrix, Cleveland, OH, USA) and quantified by A260/A280 spectrometry. The cDNA pool was generated using Superscript 3 Reverse Transcriptase (Life Technologies, Grand Island, NY, USA) according to the manufacturer\'s instructions. The cDNAs of interest and internal controls were quantified by qPCR using an iCycler (Bio-Rad, Hercules, CA, USA) platform with 2 × iQ SYBR Green Supermix (Bio-Rad) and appropriate primer sets. The PCR program was set for 40 cycles with three steps of 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s. Melting curves were obtained after PCR to ensure the homogeneity of the PCR products. The relative abundance of genes of interest was normalized to an internal control (*18S rRNA*) and depicted as mean±S.D. from three independent experiments.

Immunofluorescence microscopy
-----------------------------

HUVECs were cultured in 12-well plates, transfected with a control or two independent *p38* siRNA and followed by TNF*α* treatment. Immunofluorescence microscopy was performed using anti-PML antibodies and secondary antibodies conjugated with Alexa Fluor 594 (Invitrogen). Cells were mounted with DAPI (Vectashield; Vector Laboratories, Burlingame, CA, USA) and images were visualized using a fluorescent microscope (Leica Biosystems Inc., Buffalo Grove, IL, USA). For confocal microscopy, anti-PML and anti-protein disulfide isomerase (PDI) antibodies were used to visual whether PML localizes in the ER. The images were taken using a confocal microscope (Leica Biosystems Inc.).

Subcellular fractionation
-------------------------

HUVECs were cultured in 60 mm plates and treated with kinase inhibitors, siRNAs and TNF*α* as indicated. Before harvest, HUVECs were washed with 1 × PBS one time and spun down using a desktop centrifuge at 4 °C, 5000 r.p.m. for 5 min. The cell pellets were resuspended in five times their volume in cytosolic fractionation buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl~2~, 0.5% NP-40 and 5% glycerol) and kept on ice for 10 min. The nuclei were collected by centrifugation at 4000 r.p.m. for 6 min and the supernatants (first cytosolic fraction) were transferred to a new tube. The precipitated pellets were resuspended a second time in cytosolic fractionation buffer and spun down again. The supernatant was collected and combined with the first extract as the cytosolic fraction. The final nuclear pellets were resuspended in nuclear fraction buffer (10 mM HEPES pH 7.5, 400 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM DTT and 5% glycerol) on ice for 15 min and vortexed every 5 min until completely homogenized.

Chromatin immunoprecipitation
-----------------------------

ChIP assays were modified from our published protocol.^[@bib79]^ Briefly, HUVECs were treated with 1% formaldehyde for 10 min at room temperature and the crosslinking reaction was stopped by adding glycine to a final concentration of 0.125 M and incubated for 5 min. Cells were harvested and chromatin was sheared by sonication to an average length of 300--700 bp. Anti-HDAC7 antibody was confirmed ([Supplementary Figure 9b](#sup1){ref-type="supplementary-material"}) and used for immunoprecipitation and the immune complex was subsequently pulled down by protein A beads and washed at least 5 times by ChIP wash buffer. As a control experiment (Mock), no antibody was added. The DNA--protein complex was eluted with a freshly prepared elution buffer (50 mM NaHCO~3~, 1% SDS) at room temperature for 20 min. The eluted chromatin was incubated with 300 mM NaCl at 68 °C to reverse the crosslinks. The protein was subsequently digested with 10 mg/ml proteinase K at 45 °C for 3 h. The DNA was extracted using a DNA purification kit (Roche) and subjected to PCR analysis after RNA digestion. The results were calculated from three independent real-time PCR experiments and presented as mean±S.D. of the relative fold enrichment as the percentage of input signal. The primers for real-time PCR are listed in the [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Dual luciferase reporter assay for bicistronic reporter and cryptic promoter analysis
-------------------------------------------------------------------------------------

The bicistronic reporter plasmids or promoterless constructs were individually transfected into HUVECs, MCF7 or HeLa cells by LF2000 (Invitrogen). At 48 h post transfection, cells were harvested by adding 0.3 ml lysis buffer and mixed gently for 10 min on ice. The activities of *Renilla* (*Renilla reniformis*) luciferase (RLuc) and Firefly (*Photinus pyralis*) luciferase (FLuc) were measured using dual luciferase reporter assay (E1910; Promega) by FB12 luminometer (Berthold Technologies, Bad Wildbad, Germany) according to the manufacturer\'s instructions. Briefly, 50 *μ*l of lysate was mixed with 50 *μ*l of Luciferase Assay Reagent II to determine luminescent signal for FLuc. After the luminescence was quantified, the FLuc activity was quenched and RLuc activity was measured by adding 50 *μ*l Stop & Glo Reagent (E1910 Promega). For [Figures 4d and e](#fig4){ref-type="fig"}, a CMX-*β*-galactosidase (*β*-gal) plasmid was cotransfected with modified pRF constructs as a transfection efficiency control and the intensity of *β*-gal was measured as previously described.^[@bib5]^

*In vitro* mRNA transcription and transfection
----------------------------------------------

The DNAs containing 5′ T7 polymerase promoter and 3′ 35 nucleotide polyA tail were amplified from pRF bicistronic plasmids by specific primers as listed in the [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The amplified DNA fragments were used to *in vitro* transcribe uncapped mRNA using T7 RNA polymerase (M0251) (New England Biolabs, Ipswich, MA, USA) according to the manufacture\'s protocol. To generate capped mRNA, a 10-fold excess of RNA cap structure analog (3′-0-Me-m^7^G(5\')ppp(5\')G) was used to substitute GTP during *in vitro* transcription. After overnight transcription reaction at 37 °C, the mRNAs were purified by high pure RNA purification kit (Roche). Then, 3 *μ*g mRNA was transfected into HeLa cells in 12-well plates by LF2000 for 9 h as previously reported and the activities of RLuc and FLuc were measured as described above.^[@bib44]^ Total mRNAs were extracted from an aliquot of the transfected cells and the *Renilla* and Firefly luciferase mRNAs in each sample were determined by qRT-PCR and normalized to *18S rRNA*.

Capillary tube formation assay
------------------------------

HUVECs were transiently infected with the indicated virus expressing shRNAs. Cells were treated with trypsin and 10^4^ cells were plated on Matrigel (Millipore, Temecula, CA, USA) in 96-well plates. After seeding on the gel for 2 h, cells were treated with or without TNF*α* (20 ng/ml) in the culture medium for 12 h before image capture. Six fields per experimental group were randomly picked and the branch points in each field were counted for statistical analysis. A fraction of knockdown cells was collected to examine the knockdown efficacy by western blotting. All results are shown as mean±S.D.

Wound healing assay
-------------------

HUVECs were transiently infected with virus expressing shRNAs. The next day, the cells were plated on six-well dishes. Before they become confluent, the cells were treated with TNF*α* (20 ng/ml) for 4 h and the wounds were generated by scratching with sterile pipet tips. At 0 and 8 h after scratching, the images of six randomly chosen fields were captured by a camera equipped with microscope and the width of the same wounds was measured by ImageJ (National Institute of Health). The cell migration rate was quantified by measuring the ratio of the wound closure between 0 and 8 h. The results are shown as mean±S.D.

Trypan blue exclusion assay
---------------------------

MCF7 cells were transiently infected with lentivirus expressing shRNAs. The next day, cells were plated on 35 mm dishes followed by TNF*α* treatment. Cells were kept in DMEM containing reduced 2% FBS for 1 h before TNF*α* treatment. At 48 h after TNF*α* (60 ng/ml) treatment, cells were treated with trypsin and resuspended with 0.2% Trypan blue in 1 × PBS to examine cell viability. An aliquot of cells was loaded onto a hemacytometer and the stained dead cells and the total cells were counted in triplicate experiments. The results are shown as mean±S.D.

WST-1 cell proliferation assays
-------------------------------

5 × 10^4^ cells were seeded in 96-well plates and treated as described. WST-1 (Roche) reagents were added to the medium according to the manufacture\'s protocol. After 4 h, the number of live cells was determined by absorbance at 450--650 nm.

Colony formation assay
----------------------

3 × 10^3^ MCF7 cells were plated in 35 mm plates and treated with CGP57380 (10 *μ*M) and TNF*α* (60 ng/ml). Before treatment, medium was replaced with DMEM medium with 2% serum. Cell culture was maintained in fresh medium with CGP57380, TNF*α* or both and medium changed every 2 days. After 2 weeks, the colonies were visualized by crystal violet staining and the numbers of colonies was analyzed by ImageJ (National Institute of Health).

Detection of apoptotic and senescent cells
------------------------------------------

HUVECs were treated with TNF*α* (20 ng/ml) at the time points indicated and fixed in 4% paraformaldehyde. The apoptotic cells were determined by immunostaining using antibodies against cleaved caspase 3. Approximately 200 cells were scored in each experiment. For detection of senescent cells, senescence-associated *β*-galactosidase expression was determined by staining cells with 5-bromo-4-chloro-3-indolyl-*β*-[D]{.smallcaps}-galactopyranoside (X-gal) (B4252) (Sigma).

Polysome profiling analysis
---------------------------

HUVECs were treated with TNF*α* and CGP57380 at the indicated time. The polysome profiling analysis was performed according to a previous publication.^[@bib80]^ The cell lysates were layered over 15--54% of cold sucrose gradients in buffer (10 mM HEPES-KOH (pH 7.5), 2.5 mM MgCl~2~, 100 mM KCl). Gradients were centrifuged at 26 000 r.p.m. in a Beckman (Brea, CA, USA) SW28 rotor for 4 h at 4 °C. The relative quantity of mRNA was measured by qPCR.

Statistical analysis
--------------------

Data are presented as mean±S.D. of three independent experiments. Two compared groups were analyzed by two-tailed Student\'s *t* test. Statistical significance is presented as: n.s., not significant, \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001.
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![TNF*α* induces PML protein accumulation without changing protein stability. Accumulation of PML protein (**a**) and mRNA (**b**) during TNF*α* stimulation in HUVECs. HUVECs were treated with TNF*α* (20 ng/ml) and harvested at the indicated times. The whole-cell lysates and total RNA were prepared for western blotting with the indicated antibodies and qRT-PCR, respectively. *β*-Actin protein and *18S* rRNA were used as an internal control for western blotting and qRT-PCR, respectively. (**c** and **d**) The effect of TNF*α* on PML protein expression in HeLa cells. The experiments were similar to those in (**a**) and (**b**) except HeLa cells were used. (**d**) Quantitative measurement of the TNF*α* effect on PML protein and mRNA accumulation (*n*=3). (**e**) The effects of TNF*α* on PML protein half-life in HeLa cells were measured as described in the Materials and Methods. (**f**) The half-life of PML protein with or without TNF*α* treatment (20 h) was derived from three experiments. All the results shown in graphs are mean±S.D.](cdd2015114f1){#fig1}

![TNF*α* increases PML protein accumulation in a p38 kinase-dependent manner. (**a**) The effects of MAPK inhibitors on TNF*α*-mediated PML protein accumulation. HUVECs were pretreated with kinase inhibitors SP600125 (JNK) (10 *μ*M), SB202195 (p38) (10 *μ*M) or U0126 (ERKs) (10 *μ*M) before 16 h of TNF*α* (20 ng/ml) treatment. Cells were harvested and whole-cell lysates prepared for western blotting with the indicated antibodies. The relative ratio of PML to *β*-actin is shown in the bottom. (**b**) Inhibition of p38 kinase activity by SB202190. HUVECs were treated with DMSO or SB202190 (10 *μ*M) before TNF*α* treatment and harvested at indicated times for western blotting with the indicated antibodies. *α*-Tubulin was included as a loading control. (**c**) The effect of *p38* knockdown on TNF*α*-mediated PML protein accumulation. HUVECs were transiently transfected with a control or two independent *p38* siRNAs, treated with or without TNF*α*, harvested and western blotted with the indicated antibodies](cdd2015114f2){#fig2}

![MNKs are p38 downstream kinases that mediate TNF*α*-induced PML protein accumulation. HUVECs were pretreated with kinase inhibitors or transfected with kinase-specific siRNAs before TNF*α* treatment, followed by western blotting with the indicated antibodies. (**a**) HUVECs were treated with p38 kinase inhibitor and TNF*α* as indicated. Nuclear and cytosolic fractions were separated and subjected to western blotting. C: cytosolic fraction; N: nuclear fraction. (**b**) The effect of MSK inhibitor on TNF*α*-mediated PML protein accumulation in HUVECs. (**c**) The effect of CK2 inhibitor on TNF*α*-mediated PML protein accumulation in HUVECs. (**d**) The effect of knockdown of *MK2* on TNF*α*-mediated PML protein accumulation in HUVECs. (**e**) The effect of a MNK inhibitor on TNF*α*-mediated PML protein accumulation in HUVECs. (**f**) The effect of knockdown of *MNK1* on TNF*α*-mediated PML protein abundance and mRNA accumulation in HUVECs. The mRNA levels of PML in each sample were quantified by qRT-PCR (*n*=3). (**g**) Knockdown of *MNK1* had little or no effect on PML protein half-life in TNF*α*-treated HUVECs. Quantitation of PML protein abundance from western blots is shown on the right (*n*=4). (**h**--**j**) The effect of knockdown of *MNK2* on TNF*α*-mediated induction of PML protein in HUVECs. The mRNA levels of *PML* and *MNK2* in each sample were quantified by qRT-PCR (*n*=3). (**k**) Polysome profiling analysis demonstrates that TNF*α*--MNK1 axis controls heavy polysome occupancy on *PML* mRNA](cdd2015114f3){#fig3}

![Identification of *PML* 5′-UTR (-100-\>-1) as an IRES activated by the TNF*α--*MNK1 axis. (**a**) A schematic representation of bi-cistronic pRF plasmids used in the transient transfection reporter assays. (**b**) The effects of *PML* 5′-UTR (-100-\>-1) on reporter activity. The relative ratio of Firefly luciferase/*Renilla* luciferase intensity is plotted. The results are mean±S.D. in triplicates (*n*=3). (**c**) Determination of possible alternative splicing of the transcripts of *PML* 5′-UTR (-100-\>-1)-pRF. The cDNAs prepared from pRF or *PML* 5′-UTR (-100-\>-1)-pRF transfected HUVECs subjected to PCR using primer pairs as indicated in (**a**). The final PCR products were separated on a 0.8% agarose gel, stained by EtBr and images recorded. (**d**) Knockdown of *RLuc* in bicistronic system reduces FLuc driven by *EMCV* IRES and *PML* 5′-UTR (-100-\>-1) but not by *PML* 5′-UTR (-140-\>-1). (**e**) The reporter activity of *PML* 5′-UTR (-100-\>-1) is not derived from ribosomal read-through. HeLa cells were transiently transfected with engineered pRF and *β*-gal plasmids as indicated. At 48 h post transfection, the Firefly luciferase and *Renilla* luciferase activity were measured and normalized to the transfection control, *β*-gal. The luciferase activity of *PML* 5′-UTR (-100-\>-1)-pRF was set as 1. The results are mean ±S.D. in triplicates. (**f**) *EMCV* IRES and *PML* 5′-UTR (-100-\>-1) harbors IRES activity as evidenced by transfection of *in vitro* transcribed mRNAs into HeLa cells. The relative activity of RLuc and FLuc was normalized to the corresponding mRNA levels 9 h post transfection. (**g**) TNF*α* enhances *PML* 5′-UTR (-100-\>-1) activity in a MNK1-dependent manner. sh*Ctrl* and sh*MNK1* knockdown HeLa cells were transiently transfected with *PML* 5′-UTR (-100-\>-1)-pRF plasmid for 72 h, treated with TNF*α* at the indicated times and cells harvested. The relative activity of Firefly luciferase over *Renilla* luciferase was plotted. The results are mean ±S.D. in triplicates (*n*=3). (**h** and **i**) Ectopic expression of eIF4E inhibitor, 4E-BP or a mutant defective in phosphorylation by mTORC1, 4E-BP (5A), does not compromise TNF*α*-mediated PML protein accumulation or *PML* IRES activation. HeLa cells were transiently transfected with *PML* 5′-UTR (-100-\>-1)-pRF plasmid with the indicated plasmids for 48 h, treated with TNF*α* for 20 h and cells harvested. (**h**) Endogenous PML protein in pEBG, pEBG-4E-BP and pEBG-4E-BP (5A) transfected cells were determined by western blottings. The relative PML protein expression was normalized by *β*-actin levels and (PML)/(*β*-actin) in the absence of TNF*α* was set as 1. The relative fold induction of PML protein abundance by TNF*α* is shown in each sample. Both long (L.E.) and short (S.E.) exposures of PML western blot are shown. (**i**) The relative effect of TNF*α* on (FLuc)/(RLuc) of *PML* 5′-UTR (-100-\>-1) reporter in transfected samples is plotted. The results are shown as mean±S.D. (*n*=4)](cdd2015114f4){#fig4}

![MNK1 mediates TNF*α*-induced inhibition of cell migration and capillary tube formation in ECs. The effect of TNF*α* on HUVEC network formation (**a** and **b**) and cell migration (**c**) *in vitro*. HUVECs were subjected to capillary tube formation and wound healing assays during TNF*α* treatment as described in the Materials and Methods. Representative images in capillary tube formation assays are shown in (**a**). (**b** and **c**) All the results are mean±S.D. (*n*=6). (**d**) Knockdown efficiency of *MNK1* or *PML* in aliquots of (**e**) and (**f**). (**e**) The effect of *MNK1* or *PML* knockdown on TNF*α*-mediated inhibition of EC migration. The left panel shows representative images of wound healing assays and the right panel shows cell migration rates. (**f**) The effect of *MNK1* or *PML* knockdown on TNF*α*-mediated inhibition of *in vitro* capillary network formation. Representative images are shown in the left panel and the numbers of branches in each field were counted and quantified as shown in the right panel. (**e** and **f**) The statistical results are mean±S.D. (*n*=6)](cdd2015114f5){#fig5}

![Inhibition of PML, p38 or MNK1 decreases TNF*α*-inducible *MCP-1* and *MMP10* mRNA expression. (**a**) The effect of *PML* knockdown on *MCP-1* and *MMP10* mRNAs. The *PML* knockdown efficiency was shown in the left panel. (**b**) The effect of inhibition of p38 and MNK kinases on TNF*α*-mediated induction of *MCP-1* and *MMP10* mRNAs. The levels of *MCP-1* and *MMP10* mRNAs in each sample were measured and normalized to *18S rRNA*. (**c**) The effect of *MNK1* knockdown on TNF*α*-mediated accumulation of *MCP-1* and *MMP10* mRNAs. The statistical results are mean±S.D. (*n*=3)](cdd2015114f6){#fig6}

![TNF*α*-mediated *MCP-1* and *MMP10* mRNA expression is controlled by MNK1--PML--HDAC7 axis. (**a**, left panel) A schematic representation of the *MCP-1* promoter showing putative transcription factor binding sites that are conserved in human, chimpanzee and mouse. (**a**, right panel) The effect of TNF*α* on the association of HDAC7 with the *MCP-1* promoter analyzed by ChIP assays. (**b**) The effect of *PML* knockdown on the association of HDAC7 with the *MCP-1* promoter upon TNF*α* stimuli. The knockdown efficiency is shown in the left. (**c**) The effect of *PML* knockdown on the association of HDAC7 with the *MMP10* promoter upon TNF*α* stimuli. (**d**) The effect of *HDAC7* knockdown on TNF*α*-induced accumulation of *MCP-1* and *MMP10* mRNAs in *MNK1* and *PML* knockdown cells. HUVECs were infected with lentiviruses carrying the indicated shRNAs and treated with TNF*α*. The normalized expression of *MCP-1* and *MMP10* in HUVECs is shown. The sh*Ctrl* knockdown cells were set at 1. The knockdown efficiency of gene-specific shRNA is shown](cdd2015114f7){#fig7}

![MNK1 mediates TNF*α*-induced PML protein accumulation and apoptosis in MCF7 breast cancer cells. (**a**) The effect of inhibition of p38 and MNK1 activity on TNF*α*-induced PML protein expression in MCF7 cells. MCF7 cells were pretreated with kinase inhibitors followed by TNF*α* treatment, harvested, whole-cell lysates prepared and western blotted with the indicated antibodies. (**b**) The effect of knockdown of *MNK1* on TNF*α*-induced PML protein and mRNA accumulation. (**c**) Inhibition of MNK1 activity reduces TNF*α*-mediated PML IRES activation in MCF7 cells. MCF7 cells were transiently transfected with PML 5′-UTR (-100-\>-1)-pRF plasmid for 72 h, treated with or without MNK1 inhibitor and TNF*α* and the cells were harvested. The relative activity of Firefly luciferase to *Renilla* luciferase was plotted as shown. The results are mean±S.D. in triplicates (*n*=3). (**d** and **e**) The effect of knockdown of *MNK1* or *PML* on TNF*α*-mediated cell cytotoxicity in MFC7 cells (**d**) and the cleavage of PARP1 (**e**). MCF7 cells were infected with lentiviruses expressing a control, *MNK1* or *PML* shRNA followed by TNF*α* treatment. Aliquots of cells were used to determine cell death rate by Trypan blue exclusion assays (**d**) or cleavage of PARP1 by western blotting (**e**). The results are mean±S.D. (*n*=6). (**f**) The effect of TNF*α* and the MNK1 inhibitor CGP57380 on TNF*α*-mediated inhibition of MCF7 cell proliferation determined by colony formation assays. (**g** and **h**) The effect of TNF*α* and the MNK1 inhibitor CGP57380 on TNF*α*-mediated cell cytotoxicity in HL60 and NB4 cells by WST-1 cell proliferation assays. (**i**) A model by which TNF*α* induces anti-angiogenesis and apoptosis activity through enhancing *PML* mRNA translation that involves *PML* IRES and the p38--MNK1 axis](cdd2015114f8){#fig8}
